otilimab (GSK3196165) / GSK 
Welcome,         Profile    Billing    Logout  
 9 Diseases   1 Trial   1 Trial   139 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
otilimab (GSK3196165) / GSK
contRAst 2, NCT03970837 / 2019-000867-26: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Hourglass Jul 2022 - Dec 2022 : Data from contRAst 2 trial for moderate to severe rheumatoid arthritis with inadequate response to DMARDs
Terminated
3
1764
Europe, Japan, US, RoW
GSK3196165 (Otilimab), Tofacitinib, Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Arthritis, Rheumatoid
10/21
01/23
contRAst X, NCT04333147 / 2019-000878-30: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Terminated
3
2916
Europe, Canada, Japan, US, RoW
Otilimab (GSK3196165), csDMARD(s)
GlaxoSmithKline, Iqvia Pty Ltd
Arthritis, Rheumatoid
02/23
02/23

Download Options